Researchers have conducted one of the first studies to examine the effectiveness of nirmatrelvir-ritonavir (Paxlovid) in non-hospitalized patients during an omicron period of the COVID-19 pandemic that includes BA.4 and BA.5 subvariants.
from Medical Xpress - latest medical and health news stories https://ift.tt/uLIoRDQ
